U.S. cycling athlete Robert Pelegrin accepts sanction for anti-doping rule violation
9th December 2020,
USADA announced today that Robert Pelegrin, an athlete in the sport of cycling, has accepted a 12-month suspension for an anti-doping rule violation.
Pelegrin, 66, tested positive for anastrozole as the result of an in-competition drug test collected on August 30, 2019 at the USA Cycling Masters Track National Championships. He was selected for testing because he won his event. Anastrozole is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policy, and the Union Cycliste Internationale Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
Pelegrin’s 12-month period of ineligibility began on August 30, 2019, the date his positive sample was collected. In addition, Pelegrin has been disqualified from competitive results obtained on and subsequent to July 23, 2015, including forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to file and update athlete Whereabouts, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as an easy-reference wallet card with examples of prohibited and permitted substances, a supplement guide, a nutrition guide, an athlete handbook, and periodic alerts and advisories.
The original article can be found here.